SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer

This is an open-label, multi-center, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with NSCLC. The study includes a dose escalation phase and an expansion phase.

Trial Details

NCT ID
NCT07697586
Phase
PHASE2
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • SKB264+SKB118
Locations (sample)
  • Jilin City, China|43.84652,126.5608
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Histologically or cytologically confirmed locally advanced or metastatic NSCLC
  • Without epidermal growth factor receptor (EGFR) sensitizing mutation, and anaplastic lymphoma kinase (ALK) fusion gene.
  • Provide a tumor tissue sample.
  • At least one measurable lesion as assessed by the investigator according to RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →